carnitine has been researched along with Kidney Diseases in 56 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The improvement of malnutrition with levocarnitine in maintenance hemodialysis (MHD) patients is controversial." | 9.05 | The efficacy of L-carnitine in improving malnutrition in patients on maintenance hemodialysis: a meta-analysis. ( Yang, T; Zhou, J, 2020) |
| " Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 7.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
| " Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 7.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| "The therapeutic effect of L-carnitine on arrhythmias during hemodialysis was evaluated in 17 patients with chronic renal disease undergoing intermittent hemodialysis." | 7.66 | Effects of L-carnitine on arrhythmias during hemodialysis. ( Narita, M; Suzuki, Y; Yamazaki, N, 1982) |
| "l-carnitine (LC) is a naturally occurring compound that is administered exogenously for treatment of patients that are deficient in carnitine." | 6.46 | The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. ( Mate, A; Miguel-Carrasco, JL; Vázquez, CM, 2010) |
| "Rats fed high dosage of fructose that form a well-known experimental model of the metabolic syndrome also display progressive renal disturbances." | 5.35 | Renoprotective action of L-carnitine in fructose-induced metabolic syndrome. ( Anuradha, CV; Rajasekar, P; Viswanathan, P, 2008) |
| "The aim of this study was to evaluate to what extent secondary carnitine deficiency may exist based on the prevalence of subnormal carnitine status in patients with critical illness and abnormal nutritional state." | 5.07 | Prevalence of carnitine depletion in critically ill patients with undernutrition. ( Arfvidsson, B; Hyltander, A; Lundholm, K; Sandström, R; Sjöberg, A; Wennberg, A; Wickström, I, 1992) |
| "The improvement of malnutrition with levocarnitine in maintenance hemodialysis (MHD) patients is controversial." | 5.05 | The efficacy of L-carnitine in improving malnutrition in patients on maintenance hemodialysis: a meta-analysis. ( Yang, T; Zhou, J, 2020) |
| " Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 3.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
| " Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 3.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| "Overweight/obesity, malnutrition, and abnormalities in carnitine metabolism are recognized in kidney transplant recipients (KTRs)." | 3.80 | Nutritional status and carnitine level in kidney transplant recipients. ( Czajka, B; Dębska-Slizień, A; Małgorzewicz, S; Rutkowski, B, 2014) |
| "To evaluate the effects of L-carnitine oral supplementation on anemia and cardiac function in patients on maintenance hemodialysis (HD), we studied 55 adult chronic HD patients at our center during the period from January 2006 to June 2006 and divided them into two groups; a group of 20 patients who received 1500 mg/day oral L-carnitine and a control group of 35 patients." | 3.76 | The role of oral L-carnitine therapy in chronic hemodialysis patients. ( Sabry, AA, 2010) |
| "The therapeutic effect of L-carnitine on arrhythmias during hemodialysis was evaluated in 17 patients with chronic renal disease undergoing intermittent hemodialysis." | 3.66 | Effects of L-carnitine on arrhythmias during hemodialysis. ( Narita, M; Suzuki, Y; Yamazaki, N, 1982) |
| "L-carnitine is an important factor in fatty acid metabolism, and carnitine deficiency is common in dialysis patients." | 2.94 | Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis. ( Ichikawa, S; Io, H; Kanda, R; Kuwasawa-Iwasaki, M; Muto, M; Nakata, J; Nohara, N; Suzuki, Y; Tomino, Y; Wakabayashi, K, 2020) |
| "One of the major concerns about taking amino acid supplements is their potential adverse effects on the kidney as a major organ involved in the metabolism and excretion of exogenous substances." | 2.61 | The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders. ( Davani-Davari, D; Karimzadeh, I; Khalili, H; Sagheb, MM, 2019) |
| "l-carnitine (LC) is a naturally occurring compound that is administered exogenously for treatment of patients that are deficient in carnitine." | 2.46 | The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. ( Mate, A; Miguel-Carrasco, JL; Vázquez, CM, 2010) |
| "Carnitine is an amino acid derivative that has a key role in the regulation of fatty acid metabolism and ATP formation." | 2.43 | The use of levo-carnitine in children with renal disease: a review and a call for future studies. ( Belay, B; Esteban-Cruciani, N; Kaskel, FJ; Walsh, CA, 2006) |
| "Carnitine has a critical role in energy metabolism." | 2.36 | Carnitine. ( Borum, PR, 1983) |
| "l-carnitine is an important co-factor in fatty-acid metabolism, and its deficiency is associated with insulin resistance, which is independently associated with arterial stiffness." | 1.51 | Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation. ( Ho, GJ; Hsu, BG; Lai, YH; Lee, MC; Liu, CH, 2019) |
| "L-carnitine was administered on days 2, 3 and 4." | 1.40 | The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats. ( Akgullu, C; Boyacioglu, M; Eryilmaz, U; Kum, C; Onbasili, OA; Turgut, H, 2014) |
| "The treatment of L-carnitine also lessened gentamicin-induced renal tubular cell apoptosis in mice." | 1.35 | Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. ( Chen, CH; Chen, HH; Chen, TH; Chen, TW; Cheng, CY; Hou, CC; Hsu, YH; Lin, SL; Sue, YM; Tsai, WL, 2009) |
| "Rats fed high dosage of fructose that form a well-known experimental model of the metabolic syndrome also display progressive renal disturbances." | 1.35 | Renoprotective action of L-carnitine in fructose-induced metabolic syndrome. ( Anuradha, CV; Rajasekar, P; Viswanathan, P, 2008) |
| "Here, we describe an infant with severe Leigh syndrome, nephrotic syndrome, and CoQ(10) deficiency in muscle and fibroblasts and compound heterozygous mutations in the PDSS2 gene, which encodes a subunit of decaprenyl diphosphate synthase, the first enzyme of the CoQ(10) biosynthetic pathway." | 1.33 | Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. ( Dimauro, S; Hirano, M; Kanki, T; López, LC; Naini, A; Quinzii, CM; Rodenburg, RJ; Schuelke, M, 2006) |
| " This study indicated that there was a decrease in free carnitine levels in plasma, but there were no clinical symptoms or adverse effects associated with carnitine reduction in patients during the 7-day multiple administration of S-1108." | 1.29 | Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ( Fujita, Y; Hiraga, Y; Inamatsu, T; Nishikawa, T; Ohmichi, M; Saito, A; Shimada, J; Shimada, K; Shimizu, K; Tanimura, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (19.64) | 18.7374 |
| 1990's | 7 (12.50) | 18.2507 |
| 2000's | 15 (26.79) | 29.6817 |
| 2010's | 20 (35.71) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Emran, T | 1 |
| Chowdhury, NI | 1 |
| Sarker, M | 1 |
| Bepari, AK | 1 |
| Hossain, M | 1 |
| Rahman, GMS | 1 |
| Reza, HM | 1 |
| Lai, YH | 1 |
| Lee, MC | 1 |
| Ho, GJ | 1 |
| Liu, CH | 1 |
| Hsu, BG | 1 |
| Armaly, Z | 1 |
| Artol, S | 1 |
| Jabbour, AR | 1 |
| Saffouri, A | 1 |
| Habashi, N | 1 |
| Abd Elkadir, A | 1 |
| Ghattas, N | 1 |
| Farah, R | 1 |
| Kinaneh, S | 1 |
| Nseir, W | 1 |
| Zhou, J | 1 |
| Yang, T | 1 |
| Kuwasawa-Iwasaki, M | 1 |
| Io, H | 1 |
| Muto, M | 1 |
| Ichikawa, S | 1 |
| Wakabayashi, K | 1 |
| Kanda, R | 1 |
| Nakata, J | 1 |
| Nohara, N | 1 |
| Tomino, Y | 1 |
| Suzuki, Y | 2 |
| Koga, S | 1 |
| Kimata, T | 1 |
| Yamanouchi, S | 1 |
| Tsuji, S | 1 |
| Yoshimura, K | 1 |
| Araki, A | 1 |
| Kaneko, K | 1 |
| Chou, HC | 1 |
| Wen, LL | 1 |
| Chang, CC | 1 |
| Lin, CY | 1 |
| Jin, L | 1 |
| Juan, SH | 1 |
| Moghaddas, A | 1 |
| Dashti-Khavidaki, S | 2 |
| Davani-Davari, D | 1 |
| Karimzadeh, I | 1 |
| Sagheb, MM | 1 |
| Khalili, H | 2 |
| Jafari, A | 1 |
| Lessan-Pezeshki, M | 1 |
| Boyacioglu, M | 1 |
| Turgut, H | 1 |
| Akgullu, C | 1 |
| Eryilmaz, U | 1 |
| Kum, C | 1 |
| Onbasili, OA | 1 |
| Zambrano, S | 1 |
| Blanca, AJ | 1 |
| Ruiz-Armenta, MV | 1 |
| Miguel-Carrasco, JL | 2 |
| Arévalo, M | 1 |
| Mate, A | 2 |
| Vázquez, CM | 2 |
| Dębska-Slizień, A | 1 |
| Małgorzewicz, S | 1 |
| Czajka, B | 1 |
| Rutkowski, B | 1 |
| Fukami, K | 1 |
| Yamagishi, S | 1 |
| Sakai, K | 1 |
| Kaida, Y | 1 |
| Yokoro, M | 1 |
| Ueda, S | 1 |
| Wada, Y | 1 |
| Takeuchi, M | 1 |
| Shimizu, M | 1 |
| Yamazaki, H | 1 |
| Okuda, S | 1 |
| Kunak, CS | 1 |
| Ugan, RA | 1 |
| Cadirci, E | 1 |
| Karakus, E | 1 |
| Polat, B | 1 |
| Un, H | 1 |
| Halici, Z | 1 |
| Saritemur, M | 1 |
| Atmaca, HT | 1 |
| Karaman, A | 1 |
| Arafa, HM | 1 |
| Martinez, G | 1 |
| Costantino, G | 1 |
| Clementi, A | 1 |
| Puglia, M | 1 |
| Clementi, S | 1 |
| Cantarella, G | 1 |
| De Meo, L | 1 |
| Matera, M | 1 |
| Chen, HH | 1 |
| Sue, YM | 1 |
| Chen, CH | 1 |
| Hsu, YH | 1 |
| Hou, CC | 1 |
| Cheng, CY | 1 |
| Lin, SL | 1 |
| Tsai, WL | 1 |
| Chen, TW | 1 |
| Chen, TH | 1 |
| Caloglu, M | 1 |
| Yurut-Caloglu, V | 1 |
| Durmus-Altun, G | 1 |
| Oz-Puyan, F | 1 |
| Ustun, F | 1 |
| Cosar-Alas, R | 1 |
| Saynak, M | 1 |
| Parlar, S | 1 |
| Turan, FN | 1 |
| Uzal, C | 1 |
| Haschke, M | 1 |
| Vitins, T | 1 |
| Lüde, S | 1 |
| Todesco, L | 1 |
| Novakova, K | 1 |
| Herrmann, R | 1 |
| Krähenbühl, S | 1 |
| Al-Dirbashi, OY | 1 |
| Fisher, L | 1 |
| McRoberts, C | 1 |
| Siriwardena, K | 1 |
| Geraghty, M | 1 |
| Chakraborty, P | 1 |
| Baek, JE | 1 |
| Yang, WS | 1 |
| Chang, JW | 1 |
| Kim, SB | 1 |
| Park, SK | 1 |
| Park, JS | 1 |
| Lee, SK | 1 |
| Sabry, AA | 1 |
| Sayed-Ahmed, MM | 3 |
| Ozsoy, SY | 1 |
| Ozsoy, B | 1 |
| Ozyildiz, Z | 1 |
| Aytekin, I | 1 |
| Liu, Y | 1 |
| Van Der Leij, FR | 1 |
| Kopple, JD | 1 |
| Ding, H | 1 |
| Letoha, A | 1 |
| Ivanyi, B | 1 |
| Qing, DP | 1 |
| Dux, L | 1 |
| Wang, HY | 1 |
| Sonkodi, S | 1 |
| Walker, UA | 1 |
| Chazot, C | 1 |
| Blanc, C | 1 |
| Hurot, JM | 1 |
| Charra, B | 1 |
| Jean, G | 1 |
| Laurent, G | 1 |
| Pauly, DF | 1 |
| Pepine, CJ | 1 |
| Demirdag, K | 1 |
| Bahcecioglu, IH | 1 |
| Ozercan, IH | 1 |
| Ozden, M | 1 |
| Yilmaz, S | 1 |
| Kalkan, A | 1 |
| Eissa, MA | 1 |
| Kenawy, SA | 1 |
| Mostafa, N | 1 |
| Calvani, M | 1 |
| Osman, AM | 1 |
| Belay, B | 1 |
| Esteban-Cruciani, N | 1 |
| Walsh, CA | 1 |
| Kaskel, FJ | 1 |
| Origlia, N | 1 |
| Migliori, M | 2 |
| Panichi, V | 2 |
| Filippi, C | 1 |
| Bertelli, A | 2 |
| Carpi, A | 1 |
| Giovannini, L | 2 |
| López, LC | 1 |
| Schuelke, M | 1 |
| Quinzii, CM | 1 |
| Kanki, T | 1 |
| Rodenburg, RJ | 1 |
| Naini, A | 1 |
| Dimauro, S | 1 |
| Hirano, M | 1 |
| Aleisa, AM | 1 |
| Al-Majed, AA | 1 |
| Al-Yahya, AA | 1 |
| Al-Rejaie, SS | 1 |
| Bakheet, SA | 1 |
| Al-Shabanah, OA | 1 |
| Rajasekar, P | 1 |
| Viswanathan, P | 1 |
| Anuradha, CV | 1 |
| Narita, M | 1 |
| Yamazaki, N | 1 |
| Kudoh, Y | 1 |
| Shoji, T | 1 |
| Oimatsu, H | 1 |
| Yoshida, S | 1 |
| Kikuchi, K | 1 |
| Iimura, O | 1 |
| Borum, PR | 2 |
| Bamji, MS | 1 |
| Broquist, HP | 1 |
| Shimizu, K | 1 |
| Saito, A | 1 |
| Shimada, J | 1 |
| Ohmichi, M | 1 |
| Hiraga, Y | 1 |
| Inamatsu, T | 1 |
| Shimada, K | 1 |
| Tanimura, M | 1 |
| Fujita, Y | 1 |
| Nishikawa, T | 1 |
| Asami, T | 1 |
| Yanagihara, T | 1 |
| Tomisawa, S | 1 |
| Hayakawa, H | 1 |
| Uchiyama, M | 1 |
| Palla, R | 1 |
| Andreini, B | 1 |
| Chalmers, RA | 1 |
| Stanley, CA | 1 |
| English, N | 1 |
| Wigglesworth, JS | 1 |
| Chen, SH | 1 |
| Lincoln, SD | 1 |
| Wennberg, A | 1 |
| Hyltander, A | 1 |
| Sjöberg, A | 1 |
| Arfvidsson, B | 1 |
| Sandström, R | 1 |
| Wickström, I | 1 |
| Lundholm, K | 1 |
| Murakami, R | 1 |
| Momota, T | 1 |
| Yoshiya, K | 1 |
| Yoshikawa, N | 1 |
| Nakamura, H | 1 |
| Honda, M | 1 |
| Ito, H | 1 |
| Kelly, JG | 1 |
| Hunt, S | 1 |
| Doyle, GD | 1 |
| Laher, MS | 1 |
| Carmody, M | 1 |
| Marzo, A | 1 |
| Arrigoni Martelli, E | 1 |
| Wanner, C | 2 |
| Wieland, H | 1 |
| Wäckerle, B | 1 |
| Boeckle, H | 1 |
| Schollmeyer, P | 1 |
| Hörl, WH | 2 |
| Rebouche, CJ | 1 |
| Paulson, DJ | 1 |
| DiPalma, JR | 1 |
| Böhmer, T | 1 |
| Rydning, A | 1 |
| Solberg, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease[NCT05817799] | Phase 2/Phase 3 | 83 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes[NCT00351234] | 200 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
13 reviews available for carnitine and Kidney Diseases
| Article | Year |
|---|---|
The efficacy of L-carnitine in improving malnutrition in patients on maintenance hemodialysis: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carnitine; Dietary Supplements; Female; Humans; Kidney D | 2020 |
L-Carnitine and Potential Protective Effects Against Ischemia-Reperfusion Injury in Noncardiac Organs: From Experimental Data to Potential Clinical Applications.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Female; Gastrointestinal Diseases; Human | 2018 |
The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders.
Topics: Arginine; Athletes; Carnitine; Dietary Supplements; Dose-Response Relationship, Drug; Female; Glutam | 2019 |
Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature.
Topics: Animals; Carnitine; Humans; Kidney; Kidney Diseases | 2013 |
The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage.
Topics: Animals; Antihypertensive Agents; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Drug Deliv | 2010 |
[Inherited and acquired disorders of mitochondrial DNA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cardiomyopathies; Carnitine; Child; Dia | 2002 |
The role of carnitine in myocardial dysfunction.
Topics: Cardiomyopathies; Carnitine; Fatty Acids; Humans; Kidney Diseases; Myocardium; Renal Dialysis | 2003 |
The use of levo-carnitine in children with renal disease: a review and a call for future studies.
Topics: Anemia; Carnitine; Child; Dyslipidemias; Humans; Kidney Diseases; Kidney Failure, Chronic; Stereoiso | 2006 |
Carnitine.
Topics: Animals; Biological Transport; Carnitine; Energy Metabolism; Heart Diseases; Humans; Kidney Diseases | 1983 |
Nutritional and health implications of lysine carnitine relationship.
Topics: Animals; Carnitine; Glycine Hydroxymethyltransferase; Heart Diseases; Humans; Kidney Diseases; Liver | 1984 |
Carnitine biosynthesis: nutritional implications.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Animals; Carnitine; Child; Child, Preschool; Female | 1982 |
Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects.
Topics: Acute Kidney Injury; Carnitine; Humans; Kidney Diseases; Kidney Failure, Chronic; Renal Dialysis | 1988 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
4 trials available for carnitine and Kidney Diseases
| Article | Year |
|---|---|
Impact of pretreatment with carnitine and tadalafil on contrast-induced nephropathy in CKD patients.
Topics: Aged; Carnitine; Cross-Over Studies; Female; Haptoglobins; Humans; Kidney Diseases; Male; Phosphodie | 2019 |
Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis.
Topics: Anemia; Cardiomyopathies; Carnitine; Dietary Supplements; Female; Heart; Humans; Hyperammonemia; Jap | 2020 |
Nutritional effects of carnitine supplementation in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Carnitine; Female; Follow-Up Studies; Humans; Kidne | 2003 |
Prevalence of carnitine depletion in critically ill patients with undernutrition.
Topics: Aged; Carnitine; Critical Illness; Female; Hemofiltration; Humans; Kidney Diseases; Liver Diseases; | 1992 |
39 other studies available for carnitine and Kidney Diseases
| Article | Year |
|---|---|
L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Disease Models, Animal; Fibrosis; Inflam | 2021 |
Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation.
Topics: Adult; Ankle Brachial Index; Biomarkers; Carnitine; Cross-Sectional Studies; Down-Regulation; Female | 2019 |
Risk factors for sodium valproate-induced renal tubular dysfunction.
Topics: Adolescent; Adult; Anticonvulsants; beta 2-Microglobulin; Biomarkers; Carnitine; Chi-Square Distribu | 2018 |
From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate.
Topics: Acetylation; Alkanesulfonic Acids; Animals; Carnitine; Cell Line; Cell Movement; Cytoprotection; Dis | 2017 |
The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats.
Topics: Animals; Carnitine; Catalase; Contrast Media; Creatinine; Glutathione; Histocytochemistry; Kidney Di | 2014 |
L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ.
Topics: Animals; Carnitine; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Cytoprotection; Dise | 2014 |
Nutritional status and carnitine level in kidney transplant recipients.
Topics: Adult; Aged; Body Mass Index; Carnitine; Female; Hand Strength; Humans; Kidney Diseases; Kidney Tran | 2014 |
Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients.
Topics: Administration, Oral; Aged; Biomarkers; Carnitine; Case-Control Studies; Deficiency Diseases; Dietar | 2015 |
Nephroprotective potential of carnitine against glycerol and contrast-induced kidney injury in rats through modulation of oxidative stress, proinflammatory cytokines, and apoptosis.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Carnitine; Contrast Media; Creatinine; Cytokines; Glycerol; | 2016 |
Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Blood Urea Nitrogen; Carboplatin; Carnitine; Creatini | 2008 |
Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3.
Topics: Animals; Antineoplastic Agents; Carnitine; Cisplatin; Glomerular Mesangium; Immunohistochemistry; Ki | 2009 |
Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells.
Topics: Animals; Apoptosis; Carnitine; Cells, Cultured; Epoprostenol; Gentamicins; Kidney Diseases; Kidney T | 2009 |
Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats.
Topics: Amifostine; Animals; Carnitine; Cytoprotection; Drug Evaluation, Preclinical; Female; Kidney; Kidney | 2009 |
Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carboplatin; Carnitine; Cells, Cultured; Cisplatin; | 2010 |
Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids.
Topics: Amino Acids; Carnitine; Heptanoates; Humans; Infant, Newborn; Kidney Diseases; Liver Diseases; Neona | 2010 |
Fatty acid-bearing albumin induces VCAM-1 expression through c-Src kinase-AP-1/NF-kB pathways: effect of L-carnitine.
Topics: Albumins; Carnitine; Cell Line; CSK Tyrosine-Protein Kinase; Fatty Acids; Gene Expression; Humans; I | 2010 |
The role of oral L-carnitine therapy in chronic hemodialysis patients.
Topics: Administration, Oral; Adult; Anemia; Carnitine; Chronic Disease; Dietary Supplements; Echocardiograp | 2010 |
Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model.
Topics: Acetyl Coenzyme A; Animals; Carnitine; Cyclophosphamide; Disease Progression; Immunosuppressive Agen | 2010 |
Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study.
Topics: Animals; Blood Cells; Brain Diseases; Carnitine; Chemical and Drug Induced Liver Injury; Enzymes; He | 2011 |
Long-term effects of neonatal treatment with dexamethasone, L-carnitine, and combinations thereof in rats.
Topics: Aging; Animals; Animals, Newborn; Blood Glucose; Body Weight; Carnitine; Dexamethasone; Dose-Respons | 2011 |
L-carnitine ameliorates gentamicin-induced renal injury in rats.
Topics: Animals; Carnitine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gentamicins; Inj | 2002 |
Role of L-carnitine in the prevention of acute liver damage induced by carbon tetrachloride in rats.
Topics: Acute Disease; Animals; Carbon Tetrachloride; Carnitine; Kidney Diseases; Male; Rats; Rats, Wistar | 2004 |
Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model.
Topics: Animals; Antineoplastic Agents; Carnitine; Cisplatin; Disease Models, Animal; Kidney; Kidney Disease | 2004 |
Protective effect of L-propionylcarnitine in chronic cyclosporine-a induced nephrotoxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Carnitine; Creatinine; Cyclosporin | 2006 |
Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations.
Topics: Alkyl and Aryl Transferases; Biotin; Carnitine; Case-Control Studies; Cells, Cultured; Coenzymes; Fi | 2006 |
Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antineoplastic Agents; Blood Urea Nitrogen; | 2007 |
Renoprotective action of L-carnitine in fructose-induced metabolic syndrome.
Topics: Animals; Antioxidants; Blood Glucose; Carnitine; Fructose; Kidney Diseases; Metabolic Syndrome; Oxid | 2008 |
Effects of L-carnitine on arrhythmias during hemodialysis.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Chronic Disease; Fatty A | 1982 |
The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis.
Topics: Adolescent; Adult; Aged; Cardiomegaly; Carnitine; Cholesterol; Cholesterol, HDL; Chronic Disease; Fe | 1983 |
Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Carnitine; Cephalosporin | 1993 |
Serum carnitine concentrations in different glomerular diseases with normal renal function.
Topics: Adolescent; Carnitine; Child; Female; Humans; Kidney; Kidney Diseases; Kidney Glomerulus; Male | 1996 |
Protective effect of L-propionylcarnitine on cyclosporine-induced nephrotoxicity.
Topics: Analysis of Variance; Animals; Carnitine; Cyclosporine; Dose-Response Relationship, Drug; Kidney Dis | 1995 |
Mitochondrial carnitine-acylcarnitine translocase deficiency presenting as sudden neonatal death.
Topics: Adult; Amnion; Breast Feeding; Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransfera | 1997 |
Increased serum carnitine concentration in renal insufficiency.
Topics: Adult; Blood Urea Nitrogen; Carnitine; Coronary Disease; Humans; Kidney Diseases; Liver Cirrhosis; M | 1977 |
Serum carnitine and nutritional status in children treated with continuous ambulatory peritoneal dialysis.
Topics: Amino Acids; Blood Proteins; Carnitine; Child; Child, Preschool; Female; Humans; Infant; Kidney Dise | 1990 |
Pharmacokinetics of oral acetyl-L-carnitine in renal impairment.
Topics: Acetylcarnitine; Adult; Aged; Carnitine; Creatinine; Female; Glomerular Filtration Rate; Humans; Kid | 1990 |
Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients.
Topics: Acylation; Adult; Aged; Carnitine; Chemical Phenomena; Chemistry; Female; Humans; Hypertriglyceridem | 1989 |
L-carnitine: its therapeutic potential.
Topics: Carnitine; Chemical Phenomena; Chemistry; Diagnosis, Differential; Heart Diseases; Humans; Kidney Di | 1986 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |